Thought Leadership Highlights

Published in The Journal of Impact and ESG Investing, "From SRI to ESG: The Origins of Socially Responsible and Sustainable Investing"

It may be surprising to some that SRI has been around for decades, and ESG arrived in the mid-2000s. Inside this research paper published in The Journal of Impact and ESG Investing, “From SRI to ESG: The Origins of Socially Responsible and Sustainable Investing,” Bailard’s Blaine Townsend, CIMC®, CIMA®, EVP and Director of Sustainable, Responsible and Impact Investing, explores the history of SRI and ESG investing.

Bailard's SRII Issue Research and Outreach Library

Explore the living library of Bailard’s Sustainable, Responsible & Impact Investing (SRII) publications.

Sustainable, Responsible and Impact Investing in the age of Artificial Intelligence

Bailard’s Sustainable, Responsible and Impact Investing team examines how artificial intelligence is becoming a foundational, system-wide force across markets and portfolios—delivering both sustainability opportunities and material risks—while underscoring that its ultimate impact will depend on strong governance and responsible deployment.

September 14, 2026
Explore the shift in political giving and its impact on elections post-Citizens United. Discover how corporations influence politics.
July 8, 2026
Beneath their growing popularity lies a fundamental question: are prediction markets legitimate financial instruments, or do they function as online gambling platforms?
June 11, 2026
Artificial intelligence is reshaping markets and portfolios, creating sustainability opportunities & material risks that demand strong governance.
April 20, 2026
Explore the living library of Bailard's Sustainable, Responsible & Impact Investing (SRII) publications.
February 27, 2026
As the global economy enters a period of unprecedented expansion, geothermal energy is emerging from its niche status.
Women in wealth advocate of the year - Sonya Mughal, Bailard
February 25, 2026
Bailard CEO Sonya Mughal, CFA, has been named Women in Wealth Advocate of the Year – Individual at the 2026 Private Asset Management (PAM) Awards, presented by With Intelligence.
February 13, 2026
The 2025 U.S. proxy season marked a turn from prior years’ rising proposals, with the number of shareholder proposals filed at Russell 3000 companies decreasing for the first time in recent years.
prison cells
December 31, 2025
Read about the link between U.S. prison labor and corporate profit, and how investors can drive meaningful reform.
December 2, 2025
What advancing technology and new federal support could mean for the future of nuclear energy in the U.S.
stethoscope illustrating healthcare
September 3, 2025
The For-Profit Healthcare industry is a complex dynamic. Explore the benefits, drawbacks, and ethical questions it raises.
Pullquote: "While there has long been a revolving door between defense and government, Defense Tech seems to be arriving on the national scene hand-in-hand with this administration."
August 29, 2025
Defense technology is rapidly shifting from niche to mainstream. Blaine Townsend, Director of SRII at Bailard, explores how innovation, private capital, and government priorities are driving this change—and what it means for investors.
May 29, 2025
Artificial intelligence may soon end animal testing practices if the recent announcement by the Food and Drug Administration (FDA) reaches fruition.
May 29, 2025
Rare earth elements are vital for consumer electronics and defense technologies, and their importance to national security cannot be overstated.
October 24, 2024
Does nuclear energy provide a low-emissions solution to rapidly rising energy demands? Or does it distract investors from the stronger opportunities in renewables?
May 21, 2024
A brief diving into the importance of analyzing and collecting emissions data from investments.
April 2, 2024
The “weight loss” drug Ozempic burst onto the scene in 2023 as a juggernaut winner for Danish drug maker Novo Nordisk. What began as a drug to treat Type 2 diabetes, however, soon proved efficacious to treat a much more widespread problem: obesity. That left Novo Nordisk in the driver’s seat of a blockbuster “off-label” drug. The challenge for Novo is making sure patients with Type 2 diabetes aren’t left on the side of the road.

Keep Informed

Get the latest News & Insights from the Bailard team delivered to your inbox.

Subscribe

All investments have the risk of loss. There is no guarantee Bailard will achieve its investment objectives. Please see each full insight post for its respective disclosures.

SAN FRANCISCO235 Pine StreetSuite 1800San Francisco, CA 94104
NEW YORK875 Sixth AvenueSuite 1203New York, NY 10001
FOSTER CITY950 Tower LaneSuite 1900Foster City, CA 94404-2131

Any materials or information made available on this website are published for informational purposes only. They do not take into consideration the specific investment objectives, financial situation or particular needs of any specific recipient and should not be construed as a recommendation of, or an offer to sell or a solicitation of an offer to buy any particular security, strategy, or investment product. All investments have the risk of loss. There is no guarantee Bailard will achieve its investment objectives. Bailard does not endorse or control, either expressly or implicitly, the content posted by any third party and disclaims all comments made or information provided by non-Bailard employees. Neither Bailard nor any employee of Bailard can give tax or legal advice. The contents of this website, including any PDFs, should not be construed as, and should not be relied upon for, tax or legal advice.

Privacy Preference Center